Abstract Body

Dolutegravir (DTG) and other integrase inhibitor (INSTI) based treatments are highly effective, tolerable, and have high barriers to genetic resistance. Participants who display virological rebound on DTG-based regimens may be able to re-suppress with adherence counselling, without the risk of developing resistance and preventing switches to less tolerable or more expensive alternatives. The following analysis aims to assess the re-suppression rate following virological rebound of participants on DTG and efavirenz (EFV) based regimens in ADVANCE and NAMSAL.

In ADVANCE, 1,053 treatment-naïve participants in South Africa were randomized to TAF/FTC+DTG, TDF/FTC+DTG, or TDF/FTC/EFV600. In NAMSAL, 616 treatment-naïve participants in Cameroon were randomized to TDF/FTC+DTG or TDF/FTC/EFV400. A virological rebound(VR) event was defined as HIV-RNA >1,000 copies/mL occurring after a participant’s first undetectable reading. Following each VR event, three subsequent HIV-RNA readings were assessed to determine the proportion of events which lead to re-suppression (HIV-RNA <50 copies/mL). Participants were classified as either suppressed, unsuppressed or no follow up data. In each trial, differences between the DTG and EFV arms were tested using two sample tests of proportions. Development of drug resistance was assessed in participants with a VR event.

There was a similar number of VR-events >1,000 copies/mL in ADVANCE and NAMSAL (Table 1). In ADVANCE, the percentage of participants who re-suppressed <50 copies/mL within 3 subsequent readings was 62%, 66%, and 37% for TAF/FTC+DTG, TDF/FTC+DTG, and TDF/FTC/EFV respectively, with significant differences between the DTG and EFV groups (p<0.01). In NAMSAL, the percentage of re-suppression was 53% and 30% for participants on TDF/FTC+DTG and TDF/FTC/EFV treatments respectively (p<0.01). In ADVANCE and NAMSAL, participants on DTG-based regimens showed little development of resistance following VR events compared to participants on EFV based treatment.

In ADVANCE and NAMSAL, participants taking DTG regimens with HIV RNA >1,000 copies/mL after being suppressed were more likely to resuppress without a change in treatment with low rates of resistance. EFV based regimens were more likely to show sustained viremia and higher resistance compared to DTG based regimens.